Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6912-6923

  Shames, David S ^a   Elkins, Kristi ^a   Walter, Kimberly ^a   Holcomb, Thomas ^a   Du, Pan ^a   Mohl, Dane ^a   Xiao, Yang ^a   Pham, Thinh ^a   Haverty, Peter M ^a   Liederer, Bianca ^a   Liang, Xiaorong ^a   Yauch, Robert L ^a   O'Brien, Thomas ^a   Bourgon, Richard ^a   Koeppen, Hartmut ^a   Belmont, Lisa D ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ENZYME INHIBITOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINATE PHOSPHORIBOSYLTRANSFERASE; NICOTINATE PHOSPHORIBOSYLTRANSFERASE INHIBITOR; NICOTINIC ACID; RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DNA METHYLATION; HUMAN; IMMUNOHISTOCHEMISTRY; LETHALITY; LUNG CANCER; OVARY TUMOR; PANCREAS CANCER; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; RNA INTERFERENCE;

CELL LINE, TUMOR; CYTOKINES; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; NEOPLASMS; NIACIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PENTOSYLTRANSFERASES; PROMOTER REGIONS, GENETIC; SULFONES; TUMOR MARKERS, BIOLOGICAL;

EID: 84890759424     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1186     Document Type: Article

References (40)

1. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
2. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012;491:364-73.
3. Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 2010;10:119-25.
4. Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 2010;31:194-223.
5. Preiss J, Handler P. Enzymatic synthesis of nicotinamide mononucle-otide. J Biol Chem 1957;225:759-70.
6. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009;20: 130-8.
7. Dahl TB, Holm S, Aukrust P, Halvorsen B. Visfatin/NAMPT: a multi-faceted molecule with diverse roles in physiology and pathophysiol-ogy. Annu Rev Nutr 2012;32:229-43.
8. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-42. (Pubitemid 37413486)
9. Hjarnaa PJ, Jonsson E, Latini S, Dhar S, Larsson R, Bramm E, et al. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res 1999;59:5751-7.
10. Ravaud A, Cerny T, Terret C, Wanders J, Bui BN, Hess D, et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 2005;41:702-7. (Pubitemid 40342552)
11. Olesen UH, Christensen MK, Bjorkling F, Jaattela M, Jensen PB, Sehested M, et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008;367:799-804.
12. Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnik-off K, et al. A phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res 2002;8:2843-50. (Pubitemid 35025728)
13. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharma-cokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008; 26:45-51.
14. von Heideman A, Berglund A, Larsson R, Nygren P. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother Pharmacol 2010;65:1165-72.
15. Hara N, Yamada K, Shibata T, Osago H, Hashimoto T, Tsuchiya M. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem 2007;282:24574-82. (Pubitemid 47347525)
16. Watson M, Roulston A, Belec L, Billot X, Marcellus R, Bedard D, et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribo-syltransferase 1-deficient tumors. Mol Cell Biol 2009;29:5872-88.
17. Olesen UH, Thougaard AV, Jensen PB, Sehested M. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther 2010;9:1609-17.
18. Singh J, Zabka TS, Uppal H, Diaz D, Tarrant J, Clarke E, et al. Effects of Nicotinamide Phosphoribosyltransferase inhibitors on platelet development. Society of Toxicology Meeting; 2012; San Antonio, TX.
19. Olesen UH, Hastrup N, Sehested M. Expression patterns of nicotin-amide phosphoribosyltransferase and nicotinic acid phosphoribosyl-transferasein human malignantlymphomas. APMIS2011;119:296-303.
20. Wu TD, Nacu S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 2010;26:873-81.
21. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol 2010;11:R106.
22. Du P, Kibbe WA, Lin SM. Lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008;24:1547-8. (Pubitemid 351911712)
23. Walter K, Holcomb T, Januario T, Du P, Evangelista M, Kartha N, et al. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res 2012;18:2360-73.
24. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 2011;27:1571-2.
25. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25:2078-9.
26. Zheng X, Bauer P, Baumeister T, Buckmelter AJ, Caligiuri M, Clodfelter KH, et al. Structure-based discovery of novel amide-containing nic-otinamide phosphoribosyltransferase (Nampt) inhibitors. J Med Chem 2013;56:6413-33.
27. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
28. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995;55:5195-9.
29. Landan G, Cohen NM, Mukamel Z, Bar A, Molchadsky A, Brosh R, et al. Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nat Genet 2012;44:1207-14.
30. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
31. Brown NJ, Higham SE, Perunovic B, Arafa M, Balasubramanian S, Rehman I. Lactate dehydrogenase-B is silenced by promoter meth-ylation in a high frequency of human breast cancers. PloS ONE 2013;8: e57697.
32. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R. Methylation of the RASSF1A gene in human cancers. Biol Chem 2002;383:907-14. (Pubitemid 34874094)
33. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4:707-17. (Pubitemid 39215069)
34. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-28. (Pubitemid 351398486)
35. Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, et al. Septin 9methylated DNA is asensitive and specific blood test for colorectal cancer. BMC Med 2011;9:133.
36. Nikolaidis G, Raji OY, Markopoulou S, Gosney JR, Bryan J, Warburton C, et al. DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res 2012;72:5692-701.
37. Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res 2013;19:2265-72.
38. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 1997;57:3347-50. (Pubitemid 27355472)
39. Mancini DN, Rodenhiser DI, Ainsworth PJ, O'Malley FP, Singh SM, Xing W, et al. CpG methylation within the 5 regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene 1998;16:1161-9. (Pubitemid 28127515)
40. Ibragimova I, Cairns P. Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol 2011;780:277-91.